Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Four Months Is Worth $350m To AbbVie And Filgotinib
Why Four Months Is Worth $350m To AbbVie And Filgotinib
Why Four Months Is Worth $350m To AbbVie And Filgotinib
Submitted by
admin
on August 21, 2015 - 5:19pm
Source:
Seeking Alpha
News Tags:
AbbVie
filgotinib
FDA
review vouchers
priority review
Headline:
Why Four Months Is Worth $350m To AbbVie And Filgotinib
Do Not Allow Advertisers to Use My Personal information
